Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors
Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
- Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
- This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.
- "I am pleased to welcome General Holcomb's leadership in national security and patient care to Maxwell's board as we approach human trials next year," said Maxwell Biosciences Chairman and CEO Joshua McClure.
- "General Holcomb is a highly patient-focused medical professional with decades of deep respect within the global and national security biodefense communities.